This is a working overview of LC-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-28 and is reviewed periodically as new material appears.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
== Medical uses == Chlordiazepoxide hydrochloride is indicated for the short-term (2–4 weeks) treatment of anxiety that is severe and disabling or subjects a person to uncomfortable distress. It is also indicated as a treatment for the management of acute alcohol withdrawal syndrome. Chlordiazepoxide hydrochloride may be used by chronic benzodiazepine users to discontinue benzodiazepine use. The long half-life means that the patient’s final dose will last several days, making the likelihood of withdrawal symptoms lower. Tapering can last months to years. It is sometimes prescribed to ease symptoms of irritable bowel syndrome (IBS) when combined with clidinium bromide in the fixed dose medication, Librax.
Naturally occurring ytterbium (70Yb) is composed of seven stable isotopes: 168Yb, 170Yb–174Yb, and 176Yb, with 174Yb being the most abundant (31.90% natural abundance). 30 radioisotopes have been characterized, with the most stable being 169Yb with a half-life of 32.014 days, 175Yb with a half-life of 4.185 days, and 166Yb with a half-life of 56.7 hours. All of the remaining radioactive isotopes have half-lives that are less than 2 hours, with the majority of them being less than 20 minutes. This element also has 18 meta states, with the most stable being 169mYb (half-life 46 seconds). The known isotopes of ytterbium range from 149Yb to 189Yb. The primary decay mode before the most abundant stable isotope, 174Yb is electron capture giving thulium isotopes; the primary mode after is beta emission giving lutetium isotopes. Of interest to modern quantum optics, the different ytterbium isotopes follow either Bose–Einstein statistics or Fermi–Dirac statistics, leading to different behavior in optical lattices.
The decisive victory of Lieutenant-General Bernard Montgomery's Eighth Army over the Germans and Italians at the Second Battle of El Alamein in October–November 1942 turned the tide of the North African war strongly in favour of the Allies, and did much to revive Allied morale. The Rhodesians of the KRRC took part in the battle as part of the 7th Armoured Division under the XIII Corps, forming part of the initial thrust in the southern sector. The Rhodesian Anti-Tank Battery under Major Guy Savory also fought at El Alamein, supporting the Australian 9th Division as part of the XXX Corps. The fighting around "Thompson's Post" between 1 and 3 November was some of the fiercest Rhodesians took part in during the war. Hoping to knock out the Allied anti-tank guns before counter-attacking, the Germans concentrated intense artillery fire on the Australian and Rhodesian guns before advancing 12 Panzer IV tanks towards the weakest point of the Australian line. The Australian six-pounders had been largely disabled by the bombardment but most of the Rhodesian guns remained operational. The Rhodesian gunners disabled two Panzers and seriously damaged two more, compelling an Axis retreat, and held their position until being relieved on 3 November. One Rhodesian officer and seven other ranks were killed and more than double that number were wounded. For his actions at Thompson's Post, Sergeant J A Hotchin received the Distinguished Conduct Medal; Lieutenants R J Bawden and H R C Callon won the Military Cross and Trooper P Vorster the Military Medal.
Sources: en.wikipedia.org
Calcitonin gene-related peptide 2 (CGRP2), also called calcitonin related polypeptide beta, is a hormone that in humans is encoded by the CALCB gene (previously CALC2). Like the related hormone, calcitonin gene-related peptide 1 (CGRP1), this hormone induces vasodilation (relaxation of blood vessels) through the activation of the CGRP receptor. This form of calcitonin gene-related peptide is traditionally considered to be the primary form used in the enteric nervous system (nervous system in the gut). The gene that encodes CGRP1, CALCA, also encodes the blood-calcium-reducing hormone calcitonin, but despite its name, this protein is encoded by a distinct gene (CALCB). This hormone activates the CGRP receptor, which is a two protein (heterodimer) complex that is composed of RAMP1 and CALCRL.
Caesium-135 is a mildly radioactive isotope of caesium with a half-life of 1.33 million years. It decays via emission of a low-energy beta particle into the stable isotope barium-135. Caesium-135 is one of the seven long-lived fission products and the only alkaline one. In most types of nuclear reprocessing, it stays with the medium-lived fission products (including 137Cs which can only be separated from 135Cs via isotope separation) rather than with other long-lived fission products. As an exception, molten salt reactors create 135Cs as a completely separate stream outside the fuel (after the decay of bubble-separated 135Xe). The low decay energy, lack of gamma radiation, and long half-life of 135Cs make this isotope much less hazardous than 137Cs or 134Cs. Its precursor 135Xe has a high fission product yield (e.g., 6.3333% for 235U and thermal neutrons) but also has the highest known thermal neutron capture cross section of any nuclide. Because of this, much of the 135Xe produced in current thermal reactors (as much as >90% at steady-state full power) will be converted to practically stable 136Xe before it can decay to 135Cs despite the relatively short half-life of 135Xe. Little or no 135Xe will be destroyed by neutron capture after a reactor shutdown, or in a molten salt reactor that continuously removes xenon from its fuel, a fast neutron reactor, or a nuclear weapon.
=== Relation with kinetic theory and ideal gases === As the pressure on a gas increases, the volume of the gas decreases because the gas particles are forced closer together. Most gases behave like ideal gases at moderate pressures and temperatures. The technology of the 17th century could not produce very high pressures or very low temperatures. Hence, the law was not likely to have deviations at the time of publication. As improvements in technology permitted higher pressures and lower temperatures, deviations from the ideal gas behavior became noticeable, and the relationship between pressure and volume can only be accurately described employing real gas theory. The deviation is expressed as the compressibility factor. Boyle (and Mariotte) derived the law solely by experiment. The law can also be derived theoretically based on the presumed existence of atoms and molecules and assumptions about motion and perfectly elastic collisions (see kinetic theory of gases). These assumptions were met with enormous resistance in the positivist scientific community at the time, however, as they were seen as purely theoretical constructs for which there was not the slightest observational evidence. Daniel Bernoulli (in 1737–1738) derived Boyle's law by applying Newton's laws of motion at the molecular level. It remained ignored until around 1890, when John Waterston published a paper building the main precepts of kinetic theory; this was rejected by the Royal Society of England.
==== Near-CDP ==== Continuous Data Protection (CDP) refers to a backup that instantly saves a copy of every change made to the data. This allows restoration of data to any point in time and is the most comprehensive and advanced data protection. Near-CDP backup applications—often marketed as "CDP"—automatically take incremental backups at a specific interval, for example every 15 minutes, one hour, or 24 hours. They can therefore only allow restores to an interval boundary. Near-CDP backup applications use journaling and are typically based on periodic "snapshots", read-only copies of the data frozen at a particular point in time. Near-CDP (except for Apple Time Machine) intent-logs every change on the host system, often by saving byte or block-level differences rather than file-level differences. This backup method differs from simple disk mirroring in that it enables a roll-back of the log and thus a restoration of old images of data. Intent-logging allows precautions for the consistency of live data, protecting self-consistent files but requiring applications "be quiesced and made ready for backup." Near-CDP is more practicable for ordinary personal backup applications, as opposed to true CDP, which must be run in conjunction with a virtual machine or equivalent and is therefore generally used in enterprise client-server backups.
Sources: en.wikipedia.org
Many nonmetallic elements occur as dimers: hydrogen, nitrogen, oxygen, and the halogens fluorine, chlorine, bromine and iodine. Some metals form a proportion of dimers in their vapour phase: dilithium (Li2), disodium (Na2), dipotassium (K2), dirubidium (Rb2) and dicaesium (Cs2). Such elemental dimers are homonuclear diatomic molecules.
MODY2: Homozygous glucokinase deficiency causes severe congenital insulin deficiency resulting in persistent neonatal diabetes mellitus. About 6 cases have been reported worldwide. All have required insulin treatment from shortly after birth. The condition does not seem to improve with age. MODY4: Homozygous IPF1 results in failure of the pancreas to form. Congenital absence of the pancreas, termed pancreatic agenesis, involves deficiency of both endocrine and exocrine functions of the pancreas. Homozygous mutations in the other forms have not yet been described. Those mutations for which a homozygous form has not been described may be extremely rare, may result in clinical problems not yet recognized as connected to the monogenic disorder, or may be lethal for a fetus and not result in a viable child.
EDE is a synthetic estrane steroid and the C3 and C17β heptanoate (enanthate) diester of estradiol. It is also known as estradiol 3,17β-heptanoate or as estra-1,3,5(10)-triene-3,17β-diol 3,17β-diheptanoate. EDE is structurally related to estradiol enanthate (estradiol 17β-heptanoate), which has a single heptanoate ester rather than two.
== Treatment == Treatment is predominantly preventive. Avoidance of topical phenols and diets low in tyrosine may help. Replacement and repair of damaged tissue is also possible. Hydroquinone-induced exogenous ochronosis is an avoidable dermatosis that is exceedingly difficult to treat. However, some studies show that treatment may be possible with a Q-switched alexandrite (755 nm) laser. Individuals with this disorder are recommended to stop using hydroquinone-containing compounds. Awareness of this is important, as dermatologists may think the symptoms a patient is exhibiting are a melasma, and prescribe a hydroquinone-containing cream.
=== United States === On December 23, 2022, the DEA announced it had begun consideration on the matter of placing Diclazepam under temporary Schedule I status. Later on July 25, 2023, the DEA published a pre-print notice that Diclazepam would become temporarily scheduled as a Schedule I controlled substance from 07/26/2023 to 07/26/2025. On July 25, 2025, and effective the following day, the DEA extended the temporary scheduling until July 26, 2026.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.